A
Absci Corporation
Biotechnology: Commercial Physical & Biological Resarch company
Key Metrics of Absci Corporation
Revenue$5.7M▼ 0.5% YoYFY 2023
Operating income−$116M▼ 8.2% YoY
Net profit−$111M▼ 5.4% YoY
Shareholders' equity$176M
Market cap$1.7BABSI · $9.69
Competitors10identified
About Absci Corporation
Sectors
Company details
- Founded
- 2021
- Listed
- Nasdaq: ABSI (since 2021)
Operational Areas of Absci Corporation
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameAbsci Corporation
TickerABSI
ExchangeNasdaq
CountryUnited States
SEC CIK0001672688
Listed since2021
IndustryBiotechnology: Commercial Physical & Biological Resarch
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
ABSI · Nasdaq · SEC CIK 0001672688
Last price · 03 Nov 2026
$9.69
−12.94%
Market cap$1.7B
P/E—On FY 2023 diluted EPS
Volume3,813,257
SectorHealth CareBiotechnology: Commercial Physical & Biological Resarch
Country · IPOUnited StatesListed 2021
ABSI share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Absci Corporation
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.